Drug Pricing
Search documents
Mizuho's Jared Holz on the impact of China drug restrictions on the U.S.
CNBC Television· 2025-09-11 18:22
has drafted an executive order that would put severe restrictions on drugs from China in the name of national security. This comes as US pharma companies have been increasingly reliant on China buying rights to experimental drugs created there for everything from cancer to obesity and heart disease. For more on all this, let's bring in Jared Holtz, the healthc care equity strategist at Mizuo.Jared, great to see you. Thanks so much, Melissa. Appreciate it.Um, this has been a major source of deals so far this ...
Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback
Seeking Alpha· 2025-09-02 22:30
Group 1 - The article discusses the performance of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), highlighting an 8% increase in revenues to $14.2 billion and a GAAP net income per diluted share of $38.34 for 2024 [1] - The investing group Haggerston BioHealth provides insights into the biotech, pharma, and healthcare sectors, offering forecasts, financial statements, and market analyses [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on more than 1,000 companies [1]
Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy
Seeking Alpha· 2025-08-28 15:51
Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over five years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]
X @Bloomberg
Bloomberg· 2025-08-22 11:20
Lengthy and increasingly fraught negotiations on drug pricing between the UK government and major drugmakers ended without an agreement on Friday https://t.co/czaytpbIui ...
Novo Cuts Price of Ozempic in Half for Cash Buyers
Bloomberg Television· 2025-08-18 14:29
Market Dynamics - Novo Nordisk is aiming to regain market share from Eli Lilly in the GLP-1 market [2][10] - The obesity market is projected to reach $95 billion by 2030 [11] - Novo Nordisk is competing with compounders who offer lower-priced alternatives [4][5] Strategic Moves - Novo Nordisk is launching a cash pay version of Ozempic and expanding partnerships to increase drug accessibility [3][9] - Novo Nordisk is lowering the price of Ozempic for cash-paying patients [3][4] - Novo Nordisk already launched cash pay at cheaper Wegovy back in March for $500 per month [8] Financial Implications - The cost of Ozempic for cash-paying patients is $500 per month at the maximum dose of 2 milligrams per injection, which is $65 per milligram [4] - Compounders are offering alternatives at prices like $119.90 [5]
Eli Lilly raises price of diabetes drug Mounjaro in UK ahead of Trump deadline
CNBC Television· 2025-08-14 22:26
Lily, the best performing stock in the S&P today, up nearly 4%. The company announcing it is raising the lift price of its blockbuster diabetes drug, Monaro, in the UK. President Trump has been pressuring big pharma to get US drug prices more in line with the rest of the world most favored nation status.Let's bring in Dr. . Kavita Patel, who's an NBC News and MSNBC medical contributor. She served in the office of intergovernmental affairs and public engagement under President Obama.Dr. . Patel, great to see ...
